Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Basel

Antibody Engineering & Therapeutics Europe

The Antibody Engineering & Therapeutics Europe conference serves as the intersection of pioneering science and collaborative engagement. For over 25 years, this premier forum dedicated [...]

Go to Top